Julian Baker’s Foghorn Therapeutics FHTX Stock Holding History

Julian Baker’s Portfolio FHTX Stock Details FHTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-45,027	Closed	-$213K	–	92
2024 Q4	$213K	Hold	45,027	–	–	﹤0.01%	93
2024 Q3	$419K	Hold	45,027	–	–	﹤0.01%	90
2024 Q2	$259K	Hold	45,027	–	–	﹤0.01%	93
2024 Q1	$302K	Hold	45,027	–	–	﹤0.01%	83
2023 Q4	$290K	Hold	45,027	–	–	﹤0.01%	81
2023 Q3	$225K	Hold	45,027	–	–	﹤0.01%	100
2023 Q2	$317K	Hold	45,027	–	–	﹤0.01%	105
2023 Q1	$279K	Hold	45,027	–	–	﹤0.01%	102
2022 Q4	$287K	Hold	45,027	–	–	﹤0.01%	107
2022 Q3	$386K	Hold	45,027	–	–	﹤0.01%	109
2022 Q2	$612K	Hold	45,027	–	–	﹤0.01%	106
2022 Q1	$686K	Hold	45,027	–	–	﹤0.01%	113
2021 Q4	$1.03M	Buy	+45,027	New	+$647K	0.01%	116

Other funds holding FHTX

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Julian Baker's FHTX Position: Q1 2025 in Review

Julian Baker sold out of Foghorn Therapeutics (FHTX) in Q1 2025, closing a stake of 45,027 shares — an estimated $213K sold.

Julian Baker first reported a position in FHTX in Q4 2021 and held it in 13 quarters. The position peaked at $1.03M in Q4 2021. 90 funds tracked by Wall St. Rank hold FHTX as of Q1 2025.

Julian Baker reported no remaining Foghorn Therapeutics position as of Q1 2025 after selling out during the quarter.
Julian Baker sold 45,027 Foghorn Therapeutics shares in Q1 2025, an estimated $213K.
Julian Baker first reported a position in Foghorn Therapeutics in Q4 2021 and held it in 13 quarters.
Julian Baker's Foghorn Therapeutics position peaked at $1.03M in Q4 2021.
90 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2025.

Based on Baker Bros. Advisors's 13F filing for Q1 2025, filed 15 May 2025.